Proteins.1
Proteins.1 is a Helsinki-based Finnish deep-tech startup developing a physics-based, enzyme-free multiomics detection platform that enables ultra-sensitive single-molecule protein, DNA, and RNA analysis for life-sciences research and future clinical diagnostics.
- Company typePrivate
- Founded2026
- HeadquartersHelsinki, Finland
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Proteins.1 does
Proteins.1 is a Helsinki-based Finnish deep-tech startup that spun out from VTT Technical Research Centre of Finland in April 2026 to commercialize a patented, physics-based, enzyme-free multiomics detection platform. The company's core technology enables ultra-sensitive single-molecule protein amplification, with stated detection sensitivity up to 1,000 times higher than current gold-standard methods, and is positioned as analogous to PCR but applied to proteins without enzymes. The platform works simultaneously for DNA, RNA, and proteins, allowing researchers to detect disease markers at lower abundance, accelerate drug discovery, and access previously invisible biology. Intellectual property is protected by granted US and Finnish patents with additional international patent applications pending.
The company's go-to-market is sales-led, initially targeting research-use-only applications in oncology, neurology, and immunology, with a stated plan to progress toward regulated clinical diagnostics in the global diagnostics market. Revenue mechanics are described as hardware sales of research-use-only products first, with future regulated clinical diagnostic hardware sales as the secondary stream; pricing is not publicly disclosed and no distribution channels are yet established. The company plans a direct sales model aimed at large research institutions and pharmaceutical companies.
Proteins.1 launched with €4.7 million in pre-seed funding co-led by Lifeline Ventures and Cloudberry Ventures, with in-kind support from VTT and Business Finland. It is led by three co-founders, Harri Hallila, Prateek Singh, and Tuan Nguyen, operates with 1-10 employees out of Helsinki, and plans to expand its engineering and product development team in Finland during 2026 and 2027. The company is pre-revenue and pre-commercial launch.
Proteins.1 firmographics
Firmographics- Name
- Proteins.1
- Legal name
- Proteins1 Oy
- Website
- https://proteins1.com
- Company type
- Private
- Founded year
- 2026
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Proteins.1 is a Helsinki-based Finnish deep-tech startup developing a physics-based, enzyme-free multiomics detection platform that enables ultra-sensitive single-molecule protein, DNA, and RNA analysis for life-sciences research and future clinical diagnostics.
- Ownership category
- akta.pro rank
Where Proteins.1 is headquartered
LocationHeadquarters
- HQ city
- Helsinki
- HQ country
- Finland
- HQ region
- Europe
Offices1 record
Markets served
Proteins.1 business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Research-Use-Only Products: Initial revenue stream from research-use-only applications in oncology, neurology, and immunology before advancing to regulated clinical diagnostics.
- Clinical Diagnostics: Future regulated clinical diagnostics targeting the global diagnostics market.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels2 records
Proteins.1 product offering
Product offeringCore offering
Proteins.1 commercializes a physics-based, enzyme-free multiomics platform that enables ultra-sensitive single-molecule protein detection and simultaneous analysis of DNA, RNA, and proteins. The platform delivers up to 1,000 times higher detection sensitivity than current gold-standard methods, targeting research-use-only applications in oncology, neurology, and immunology with a future pathway into regulated clinical diagnostics.
Product overview
Proteins.1 is a single unified product platform — an enzyme-free, physics-based multiomics detection platform that enables ultra-sensitive single-molecule protein amplification. The platform works simultaneously for DNA, RNA, and proteins, delivering detection sensitivity up to 1,000 times higher than current gold-standard methods. The company initially targets research-use-only applications in oncology, neurology, and immunology before progressing toward regulated clinical diagnostics in the global diagnostics market.
Differentiator
Problem solved
Functional benefit
Products and services
- Proteins.1 Platform Physics-based, enzyme-free multiomics detection platform enabling ultra-sensitive single-molecule protein detection with simultaneous analysis of DNA, RNA, and proteins. Provides detection sensitivity up to 1,000 times higher than current gold-standard methods, targeting early disease detection, biomarker research, and drug discovery applications in oncology, neurology, and immunology.
Quantifiable outcome
- Detection sensitivity up to 1,000 times higher than current gold-standard platforms
Companies that use Proteins.1
Customer profileSegments2 records
Ideal customer profiles2 records
Proteins.1 technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature1 record
Proteins.1 partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- VTT Technical Research Centre of FinlandcoreParent organization from which Proteins.1 spun off. Provided in-kind support and originally developed the patented technology. VTT continues as a strategic partner for research and development.
Scale indicators3 records
Recent moves8 records
Expansion highlights5 records
Proteins.1 competitors and assessment
Company assessmentDirect peers
- Olink Holding: Olink provides high-multiplex proximity extension assay-based proteomics platforms serving pharma and academic research customers in oncology, neurology, and immunology — directly overlapping Proteins.1's initial target use cases.
- Quanterix: Quanterix commercializes ultra-sensitive single-molecule protein detection via its Simoa platform, the closest direct competitor to Proteins.1's core single-molecule protein amplification technology. Both target low-abundance biomarker discovery and clinical diagnostics.
- SomaLogic: SomaLogic offers SomaScan, a large-scale proteomics platform for biomarker discovery and disease research, serving pharma and clinical research customers in similar applications to Proteins.1.
- Standard BioTools (formerly Fluidigm): Standard BioTools provides mass cytometry and microfluidic instrumentation for single-cell multiomics workflows. Its technologies overlap with Proteins.1's goal of single-molecule, multi-analyte detection.
Broad incumbents
- 10x Genomics: 10x Genomics offers single-cell multiomics platforms (Chromium, Visium) for simultaneous genomics and proteomics research. While its core is single-cell genomics, its multiomics roadmap overlaps Proteins.1's simultaneous DNA/RNA/protein vision.
- Bio-Techne: Bio-Techne provides proteomics reagents, ELISA kits, and analytical tools (including the ProteinSimple branded Western blot and Simple Plex platforms) used in the same research workflows Proteins.1 aims to disrupt.
- Abcam: Abcam supplies antibodies and proteomics research tools widely used in protein detection workflows that Proteins.1's enzyme-free approach aims to bypass. Recently acquired by Danaher.
- Illumina: Illumina is the dominant sequencing platform vendor and increasingly active in proteomics-adjacent multiomics. Its installed base and clinical-diagnostics channel are relevant comparables for Proteins.1's regulated diagnostics ambitions.
- Thermo Fisher Scientific: Thermo Fisher's life-sciences instruments division supplies mass spectrometry, qPCR, and proteomics workflows used by the same research and clinical customers Proteins.1 targets. It also sells diagnostic instruments through its specialty diagnostics segment.
Emerging players
- Quantum-Si: Quantum-Si is an early-stage company developing single-molecule protein sequencing using semiconductor chip technology — an alternative architectural approach to next-generation protein detection with similar ambitions to Proteins.1.
Market position
Strengths1 record
Weaknesses1 record
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Proteins.1 social profiles
Digital presenceProteins.1 financial estimates
Financial estimateRevenue estimate
Valuation estimate
Proteins.1 leadership team
Management profileNumber of profiles
Profiles3 records
Proteins.1 funding detail
Funding detailFunding overview
Funding rounds1 record
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Proteins.1 M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Proteins.1
What does Proteins.1 do?
Proteins.1 commercializes a physics-based, enzyme-free multiomics platform that enables ultra-sensitive single-molecule protein detection and simultaneous analysis of DNA, RNA, and proteins. The platform delivers up to 1,000 times higher detection sensitivity than current gold-standard methods, targeting research-use-only applications in oncology, neurology, and immunology with a future pathway into regulated clinical diagnostics.
Is Proteins.1 a public or private company?
Proteins.1 is a private company. It is classified as venture growth investor backed and is currently operating.
When was Proteins.1 founded?
Proteins.1 was founded in 2026. It employs 1 to 10 people.
Where is Proteins.1 based?
Proteins.1 is headquartered in Helsinki, Finland, in the Europe region.
How does Proteins.1 make money?
Two revenue lines are on record. Research-Use-Only Products are the primary driver. The others are clinical Diagnostics.
Who are Proteins.1's main competitors?
Direct peers on record are Olink Holding, Quanterix, SomaLogic and Standard BioTools (formerly Fluidigm). Broad incumbents are 10x Genomics, Bio-Techne, Abcam, Illumina and Thermo Fisher Scientific. Quantum-Si is listed as an emerging player.
Does Proteins.1 have an API?
No public API is recorded for Proteins.1.